Bristol Myers Squibb (CELG-RI) FCF Payout Ratio Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) FCF Payout Ratio Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-0.92% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
-94.03% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
141.61% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-58.56% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-58.88% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-29.55% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
-29.45% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-18.46% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
128.23% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
128.23% |
| Date | Value |
|---|
| Mar 31, 2026 |
128.23% |
| Dec 31, 2025 |
162.33% |
| Sep 30, 2025 |
-8.69% |
| Jun 30, 2025 |
-39.81% |
| Mar 31, 2025 |
56.24% |
| Dec 31, 2024 |
1.41% |
| Sep 30, 2024 |
-14.53% |
| Jun 30, 2024 |
-19.81% |
| Mar 31, 2024 |
6.98% |
| Dec 31, 2023 |
-23.54% |
| Sep 30, 2023 |
-19.48% |
| Jun 30, 2023 |
12,086.90% |
| Mar 31, 2023 |
33.43% |
| Dec 31, 2022 |
31.53% |
| Sep 30, 2022 |
53.76% |
| Jun 30, 2022 |
114.93% |
| Mar 31, 2022 |
9.71% |
| Dec 31, 2021 |
-11.51% |
| Sep 30, 2021 |
-54.60% |
| Jun 30, 2021 |
-98.80% |
